Sentences with phrase «with immune effectors»

The «kick - and - kill» paradigm is aimed at combining latency reversing agents (LRA) with immune effectors, such as T - cells, to wake up the virus and kill the reactivated cells.

Effector and target modules together form a novel platform which allows us to engage target cells (e.g. tumor cells, virus infected cells) directly with immune effector cells.

Not exact matches

They systematically deleted genes for secreted effector proteins — molecules that the parasite injects into a host cell to modulate the immune system during infection — and injected the altered parasites into mice with aggressive ovarian cancer.

Innate immune effector cells, including natural killer cells, macrophages, and dendritic cells, have been shown to interact with cancers and inhibit their progression.

The HZI will develop a vaccination protocol for mucosal administration based on three novel strategies: (i) development and optimization of a vaccination protocol in which parenterally - primed T and B cells are subsequently pulled into the mucosa by the local delivery of the cognate antigen to the requested effector site, (ii) testing the co-administration of antigens with novel mucosal adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both systemic and mucosal immune responses following transcutaneous / trans - follicular vaccination.

She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.

While it is not straightforward to directly compare the immune repertoire reported here with previous reports that have used different underlying gene models [15], [34], we do note that our inference about the number and identity of signaling components is consistent with previous annotations [15], [34], while our inference about recognition and effectors tends to reflect greater, albeit still relatively minor, differences.

Based on these sources, we identify 497 genes with possible immune function in Nasonia (Table S1), including 75 encoding effectors (AMPs, proteins in the prophenoloxidase cascade, transferrins, and peroxidases), 96 encoding recognition proteins (including PGRPs, TEPs, Nimrod - like proteins, and numerous lectins), 101 encoding signaling proteins, and 225 encoding proteases or protease inhibitors.

The innate immune system is particularly amenable to characterization with expression - based methodology such as RNA - seq, as one of the key biological consequences of pathogenic infections is the rapid induction of several classes of effector proteins, along with up - regulation of a number of other pathway components.

Therefore the group studies with sophisticated imaging technology in vitro and ex vivo: i) the molecular mechanism driving the migration of HIV through the intestinal epithelial barrier; ii) the cellular targets in the mucosa, in specific macrophages and DCs, to identify the possible pathways to invade the tissue and disseminate to other organs; iii) the involvement of DCs and their functional properties in mediating adaptive immune responses at mucosal level; and iv) the role of antibodies with different effector functions in changing the pathways of the virus.

Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels